###begin article-title 0
###xml 54 62 <span type="species:ncbi:9606">children</span>
A role for MCP-1/CCR2 in interstitial lung disease in children
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 305 307 305 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
Interstitial lung diseases (ILD) are chronic inflammatory disorders leading to pulmonary fibrosis. Monocyte chemotactic protein 1 (MCP-1) promotes collagen synthesis and deletion of the MCP-1 receptor CCR2 protects from pulmonary fibrosis in ILD mouse models. We hypothesized that pulmonary MCP-1 and CCR2+ T cells accumulate in pediatric ILD and are related to disease severity.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 239 241 239 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 250 252 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 50 58 <span type="species:ncbi:9606">children</span>
###xml 83 91 <span type="species:ncbi:9606">children</span>
Bronchoalveolar lavage fluid was obtained from 25 children with ILD and 10 healthy children. Levels of pulmonary MCP-1 and Th1/Th2-associated cytokines were quantified at the protein and the mRNA levels. Pulmonary CCR2+, CCR4+, CCR3+, CCR5+ and CXCR3+ T cells were quantified by flow-cytometry.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 250 252 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 62 70 <span type="species:ncbi:9606">children</span>
###xml 176 184 <span type="species:ncbi:9606">Children</span>
###xml 317 325 <span type="species:ncbi:9606">children</span>
CCR2+ T cells and MCP-1 levels were significantly elevated in children with ILD and correlated with forced vital capacity, total lung capacity and ILD disease severity scores. Children with lung fibrosis had significantly higher MCP-1 levels and CCR2+ T cells in bronchoalveolar lavage fluid compared to non-fibrotic children.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The results indicate that pulmonary CCR2+ T cells and MCP-1 contribute to the pathogenesis of pediatric ILD and might provide a novel target for therapeutic strategies.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 215 223 <span type="species:ncbi:9606">children</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Interstitial lung diseases (ILD) are chronic inflammatory disorders characterized by restrictive lung disease and diffuse pulmonary infiltrates. Although the precise incidence is not known, ILD are less frequent in children than adults [1-3]. Lungs of ILD patients show inflammation with alveolar wall thickening by leukocytes and pulmonary fibrosis. Despite immunosuppressive treatment and supportive measures, the progressive course leading to irreversible lung fibrosis sometimes can not be prevented. Therefore, the development of additional therapeutic strategies is of high importance.
###end p 11
###begin p 12
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 399 400 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 401 402 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 601 602 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 603 605 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 648 650 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 651 653 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 739 748 730 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 800 802 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 865 867 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1016 1018 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1120 1122 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1139 1141 1130 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 431 437 <span type="species:ncbi:10090">murine</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 1003 1009 <span type="species:ncbi:10090">murine</span>
###xml 1042 1046 <span type="species:ncbi:10090">mice</span>
###xml 1160 1168 <span type="species:ncbi:9606">patients</span>
Monocyte chemotactic protein 1 (MCP-1, CCL2) is produced in response to inflammatory stimuli by a variety of cells, including monocytes/macrophages, lymphocytes and airway epithelial cells [4-6]. MCP-1 stimulates collagen synthesis and production of the pro-fibrotic factor transforming growth factor beta (TGF-beta) in fibroblasts, while MCP-1 antisense oligonucleotides reduce TGF-beta production[7,8]. Application of MCP-1 into murine lungs induces an inflammatory cytokine response and pulmonary leukocyte accumulation. In adult patients with ILD, increased levels of MCP-1 were observed in serum[9,10] and bronchoalveolar lavage fluid (BALF) [11-14]. Although MCP-1 was originally described for its chemotactic activity on monocytes, in vitro studies revealed an even higher activity on T cells[15]. This occurs through MCP-1 binding to its sole receptor CCR2[16]. Deletion of the CCR2-gene or receptor blockade with anti-CCR2 antibodies leads to a dramatic inhibition of leukocyte accumulation in murine lungs[17]. Furthermore, CCR2-/- mice are protected from fluorescein (FITC) or bleomycin induced lung fibrosis[18]. Thus far, CCR2+ T cells in BALF of patients with fibrotic lung diseases have not been determined.
###end p 12
###begin p 13
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 205 207 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 208 210 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 364 365 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 459 461 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 526 528 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 566 568 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 222 227 <span type="species:ncbi:10090">mouse</span>
###xml 352 357 <span type="species:ncbi:10090">mouse</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
In addition to the MCP-1/CCR2 axis, Th2 cytokines seem to mediate pulmonary fibrosis [19-22]. IL-4 stimulates fibroblast proliferation and collagen synthesis[23,24], while IFN-gamma inhibits this process [25-28]. In a Th2 mouse model fibroblasts expressed more CCR2 protein and higher levels of MCP-1 and TGF-beta as compared to fibroblasts from a Th1-mouse model[8]. Furthermore, increased levels of IL-4 were observed in animal models of pulmonary fibrosis[29] and lungs of patients with idiopathic pulmonary fibrosis (IPF)[30] or cryptogenic fibrosing alveolitis[31].
###end p 13
###begin p 14
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 147 155 <span type="species:ncbi:9606">children</span>
###xml 185 193 <span type="species:ncbi:9606">children</span>
The contribution of MCP-1 to ILD has been investigated exclusively in adults. However, the spectrum of ILD differs considerably between adults and children and some forms are unique to children while others, such as idiopathic pulmonary fibrosis (IPF), are extremely rare in childhood[32].
###end p 14
###begin p 15
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 160 162 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 102 110 <span type="species:ncbi:9606">children</span>
Therefore, we asked whether levels of MCP-1 and frequencies of CCR2+ T cells are increased in BALF of children with ILD and, if so, how levels of MCP-1 and CCR2+ T cells relate to disease severity in pediatric ILD.
###end p 15
###begin p 16
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 106 114 <span type="species:ncbi:9606">children</span>
###xml 128 136 <span type="species:ncbi:9606">children</span>
To address these questions levels of MCP-1 and frequencies of CCR2+ T cells in BALF were compared between children with ILD and children without lung disease.
###end p 16
###begin p 17
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 145 147 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
To evaluate the contribution of the pulmonary Th1/Th2 micromilieu to the pathogenesis of pediatric ILD, CCR4+ and CCR3+ (Th2) and CCR5+ and CXCR3+ (Th1) cells were determined in BALF together with an array of pulmonary Th1- and Th2-associated cytokines.
###end p 17
###begin p 18
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 111 119 <span type="species:ncbi:9606">children</span>
Our results indicate that pulmonary CCR2+ T cells and levels of MCP-1 are characteristic components in BALF of children with ILD. A pathophysiological role in pediatric ILD seems likely as their levels relate to restrictive lung function and ILD disease severity.
###end p 18
###begin title 19
Methods
###end title 19
###begin title 20
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Characterization of the patients
###end title 20
###begin p 21
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 886 888 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 0 8 <span type="species:ncbi:9606">Children</span>
###xml 83 91 <span type="species:ncbi:9606">Children</span>
###xml 175 183 <span type="species:ncbi:9606">Children</span>
###xml 259 266 <span type="species:ncbi:9606">patient</span>
###xml 443 451 <span type="species:ncbi:9606">Children</span>
Children attending the Department of Pulmonology and Allergology of the University Children's Hospital of Munich during 1999-2004 were considered for inclusion in this study. Children suspective of ILD underwent a comprehensive clinical evaluation, including patient history, physical examination, routine laboratory tests, lung function testing, chest radiography, high resolution computed tomography (HRCT) and bronchoalveolar lavage (BAL). Children were assigned to the ILD group according to the criteria of Fan[33]: (i) >/=3 months of respiratory symptoms characteristic for ILD, i.e. non-productive cough, dyspnoea, tachypnea, crackles and/or rales, exercise intolerance and/or hypoxemia, (ii) diffuse infiltrates on chest radiographs and HRCT and (iii) restrictive lung function (decreased forced vital capacity (FVC) and total lung capacity (TLC)) according to the ATS criteria[34].
###end p 21
###begin p 22
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 61 68 <span type="species:ncbi:9606">patient</span>
###xml 461 468 <span type="species:ncbi:9606">patient</span>
###xml 750 758 <span type="species:ncbi:9606">children</span>
###xml 803 811 <span type="species:ncbi:9606">Patients</span>
The diagnosis of the specific form of ILD was established by patient history, physical examination, HRCT, BAL and/or lung biopsy according to consensus criteria[33,35]. Two thoracic radiologists independently evaluated all lobes on HRCT for ground glass opacity and pulmonary fibrosis as described previously[36,37]. A pathologist specialized on pediatric ILD[38] evaluated the lung sections systematically[39,40]. Furthermore, the disease severity of each ILD patient was characterized using the clinical ILD score of Fan[41]: 1 = asymptomatic, no desaturation; 2 = symptomatic but normoxic (>90%) under all conditions; 3 = symptomatic with desaturation during sleep or with exercise; 4 = symptomatic with desaturation at rest. None of the included children had familial idiopathic pulmonary fibrosis. Patients with congenital heart disease or suspected or proven bacterial pulmonary infection were excluded from the study.
###end p 22
###begin p 23
###xml 101 102 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 12 20 <span type="species:ncbi:9606">children</span>
Twenty-five children with ILD (median age: 7 +/- 3.6 years; male/female = 16/9) were included (Table 1).
###end p 23
###begin p 24
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' characteristics
###end p 24
###begin p 25
###xml 8 16 <span type="species:ncbi:9606">children</span>
###xml 98 106 <span type="species:ncbi:9606">children</span>
ILD-NC: children with interstitial lung disease without systemic corticosteroid treatment; ILD-C: children with interstitial lung disease with systemic corticosteroid treatment;
###end p 25
###begin p 26
U-ILD: undefined/idiopathic interstitial lung disease: no specific diagnosis could be made; PAP: pulmonary alveolar proteinosis; CGD: chronic granulomatous disease; IPH: idiopathic pulmonary hemosiderosis; LIP: lymphocytic interstitial pneumonia; CPI: Chronic pneumonitis of infancy
###end p 26
###begin p 27
CS: corticosteroids, AZT: azathioprine, MT: methotrexat
###end p 27
###begin p 28
###xml 38 46 <span type="species:ncbi:9606">children</span>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
n.d.: lung function testing not done (children < 5 years); dagger symbolizes patients who died due to respiratory failure.
###end p 28
###begin p 29
CT: Computed tomography; BAL: Bronchoalveolar lavage; LB: Lung biopsy
###end p 29
###begin p 30
* ILD score according to Fan[41]
###end p 30
###begin p 31
###xml 16 24 <span type="species:ncbi:9606">children</span>
###xml 109 117 <span type="species:ncbi:9606">children</span>
###xml 274 282 <span type="species:ncbi:9606">children</span>
Ten age-matched children were selected as the control group (median age: 7.5 +/- 2.9 years, m/f: 6/4). These children were considered as healthy, i.e. had no systemic disease, had no suspected or proven pulmonary disease and were free of respiratory tract infections. These children underwent elective tonsillectomy under general anaesthesia. BAL was performed prior to the surgical procedure.
###end p 31
###begin p 32
###xml 117 119 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 16 24 <span type="species:ncbi:9606">children</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
Ten age-matched children with chronic severe asthma (median age: 8.7 +/- 1.6 years, m/f: 5/5), from a previous study[42], who were comparable to the ILD group in terms of gender and age were included as disease control group. All parents and/or patients gave their informed consent prior to bronchoscopy and the institutional review board approved the study protocol.
###end p 32
###begin title 33
Bronchoalveolar lavage
###end title 33
###begin p 34
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 201 208 <span type="species:ncbi:9606">patient</span>
Bronchoscopy with BAL was performed as described previously[43]. Residual BALF cells were used for flow cytometry. The BALF recovery and the viability of cells did not differ significantly between the patient groups. Cellular profiles are shown in Table 2.
###end p 34
###begin p 35
Bronchoalveolar lavage cells
###end p 35
###begin p 36
results are expressed as medians with ranges shown in parenthesis.
###end p 36
###begin p 37
###xml 8 16 <span type="species:ncbi:9606">children</span>
ILD-NC: children with interstitial lung disease without systemic corticosteroid treatment;
###end p 37
###begin p 38
###xml 7 15 <span type="species:ncbi:9606">children</span>
ILD-C: children with interstitial lung disease with systemic corticosteroid treatment;
###end p 38
###begin p 39
###xml 69 71 69 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
*p < 0.05, **p < 0.01 as compared to the control group, Mann-Whitney-U Test.
###end p 39
###begin p 40
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 85 87 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Total cells and differential cell count were obtained from cytospin slides, CD4+, CD8+ and CD4/CD8 T cells using flow cytometry.
###end p 40
###begin p 41
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 9 11 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 26 28 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
daggerCD4+ T cells and CD8+ T cells are shown as the percentage of total lymphocytes in BALF, i.e. cells gated in the lymphocyte population. Neutrophils, eosinophils, mast cells, plasma cells, macrophages and lymphocytes are shown as percentage of total cells in BALF.
###end p 41
###begin title 42
Flow cytometry
###end title 42
###begin p 43
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 200 205 <span type="species:ncbi:10090">mouse</span>
###xml 237 242 <span type="species:ncbi:10090">mouse</span>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 309 314 <span type="species:ncbi:10090">mouse</span>
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
###xml 388 393 <span type="species:ncbi:10090">mouse</span>
###xml 441 446 <span type="species:ncbi:10090">mouse</span>
###xml 466 469 <span type="species:ncbi:10116">rat</span>
###xml 511 516 <span type="species:ncbi:10090">Mouse</span>
###xml 528 533 <span type="species:ncbi:10090">mouse</span>
###xml 543 548 <span type="species:ncbi:10090">mouse</span>
###xml 559 564 <span type="species:ncbi:10090">mouse</span>
###xml 610 613 <span type="species:ncbi:10116">rat</span>
BALF cells were analyzed by four-colour flow cytometry (FACSCalibur, Becton-Dickinson, Heidelberg, Germany) as described previously[42]. The following antibodies were used: CD4-allophycocyanine (APC) mouse IgG1, CD8-phycocyanine 5 (PC5) mouse IgG1 (Immunotech, Marseille, France), CD69-PE mouse IgG1, CCR5-PE mouse IgG2a, CCR4-PE mouse IgG2a (BD Pharmingen, Heidelberg, Germany), CCR2-PE mouse IgG2b, CXCR3-fluorescein isothiocyanate (FITC) mouse IgG1 and CCR3-FITC rat IgG2a (R&D Systems, Wiesbaden, Germany). Mouse IgG1-FITC, mouse IgG1-PE, mouse IgG2a-PE, mouse IgG2b-PE (Immunotech, Marseille, France) and rat IgG2a-FITC (kindly provided by Dr. E. Kremmer, GSF-Institute of Molecular Immunology, Munich, Germany) were used as isotype controls.
###end p 43
###begin title 44
Detection of MCP-1 and cytokines
###end title 44
###begin p 45
###xml 234 236 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Levels of MCP-1 and Th1 (IL-2, IFN-gamma), Th2 (IL-4, IL-5, IL-10) and pro-inflammatory cytokines (TNF-alpha, IL-6) were quantified by a multiplex, particle-based assay (Bio-Rad Laboratories, Minneapolis, USA) as described previously[42]. The detection limits for all cytokines were 1.5-2.5 pg/ml (min.) and 1000 pg/ml (max.).
###end p 45
###begin title 46
Quantitative RT-PCR
###end title 46
###begin p 47
BALF cells were lysed in Trizol LS Reagent (Invitrogen, Life Technologies, Karlsruhe, Germany) and were stored at -20degreesC until mRNA extraction. Total mRNA was isolated according to the manufacturer's instructions and reverse transcribed into cDNA. Contamination with genomic DNA was excluded by mRNA controls without reverse transcriptase in the cDNA synthesis reaction. The following oligonucleotide primers were used: MCP-1 (5-TGAAGCTCGCACTCTCGCCT-3; 5- GTGGAGTGAGTGTTCAAGTC-3); and GAPDH (5-GAGGTGAAGGTCGGAGTC-3; 5-AAGATGGTGATGGGATTTC-3). Expression levels were determined in duplicates by Real time RT-PCR using SYBR green and the iCycler iQ detection system (Biorad, Hercules, CA, USA) according to the manufacturer's instructions. Threshold cycle (CT) values for genes of interest were normalized to GAPDH and used to calculate the relative mRNA expression.
###end p 47
###begin title 48
Statistical analysis
###end title 48
###begin p 49
###xml 32 34 32 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
The non-parametric Mann-Whitney U test was applied. Correlations were tested with Spearman's rank correlation test. A probability of p < 0.05 was regarded as significant[44] (SPSS statistical program, version 11.5, SPSS Inc. Chicago, USA).
###end p 49
###begin title 50
Results
###end title 50
###begin title 51
###xml 21 23 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
MCP-1 levels and CCR2+ T cells in BALF
###end title 51
###begin p 52
###xml 139 144 139 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A, B</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 694 699 694 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A, B</xref>
###xml 45 53 <span type="species:ncbi:9606">children</span>
###xml 252 260 <span type="species:ncbi:9606">children</span>
###xml 346 354 <span type="species:ncbi:9606">children</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
Levels of MCP-1 were significantly higher in children with ILD (n = 25) as compared to the control group at protein and mRNA level (Figure 1A, B). MCP-1 protein and mRNA expression levels correlated positively with each other (r = 0.72, p < 0.01). ILD children with pulmonary fibrosis had significantly higher MCP-1 levels in BALF as compared to children with non-fibrotic ILD (Figure 1C). MCP-1 levels related positively to the stage of disease (Figure 1D). The highest levels of MCP-1 were observed in the three patients who died after respiratory failure (Table 1; P17, P19, P22). Furthermore, MCP-1 levels correlated negatively with restrictive lung function parameters (TLC, FVC) (Figures 2A, B).
###end p 52
###begin p 53
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 levels in children with ILD</bold>
###xml 1119 1121 1119 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 16 24 <span type="species:ncbi:9606">children</span>
###xml 90 98 <span type="species:ncbi:9606">children</span>
###xml 246 254 <span type="species:ncbi:9606">children</span>
###xml 393 401 <span type="species:ncbi:9606">children</span>
###xml 1070 1077 <span type="species:ncbi:9606">patient</span>
###xml 1154 1162 <span type="species:ncbi:9606">Children</span>
###xml 1295 1303 <span type="species:ncbi:9606">children</span>
MCP-1 levels in children with ILD. MCP-1 levels in bronchoalveolar lavage fluid (BALF) of children with interstitial lung diseases (ILD) and healthy controls are shown at the (A) protein and at the (B) mRNA level. (C) MCP-1 levels in BALF of ILD children with and without pulmonary fibrosis. Pulmonary fibrosis was assessed by computed tomography according to [36,37]. (D) MCP-1 levels in ILD children related to ILD disease severity according to the criteria of Fan [33]. 1 = asymptomatic, no desaturation; 2 = symptomatic but normoxic (> 90%) under all conditions; 3 = symptomatic with desaturation during sleep or exercise; 4 = symptomatic with desaturation at rest; MCP-1 protein levels were quantified in BALF by a multiplex, particle-based assay (Bio-Rad Laboratories, Minneapolis, USA) as described previously [42]. MCP-1 mRNA levels were quantified in BALF cells by Real time RT-PCR using SYBR green and the iCycler iQ detection system (Biorad, Hercules, CA, USA) and were normalized to GAPDH. Median values are shown by horizontal bars. Differences between the patient groups were tested with the Mann-Whitney U test; * p < 0.05, *** p < 0.001; Children with systemic corticosteroid therapy are shown as grey circles. P: Pulmonary alveolar proteinosis; S: Sarcoidosis; dagger symbolize children who died due to respiratory failure.
###end p 53
###begin p 54
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlation of MCP-1 levels with lung function parameters in children with ILD</bold>
###xml 61 69 <span type="species:ncbi:9606">children</span>
###xml 217 225 <span type="species:ncbi:9606">children</span>
Correlation of MCP-1 levels with lung function parameters in children with ILD. MCP-1 levels in bronchoalveolar lavage fluid (BALF) correlated with (A) forced vital capacity (FVC) and (B) total lung capacity (TLC) in children with interstitial lung disease (ILD). FVC and TLC are shown as % of predicted. MCP-1 levels in BALF were quantified by a multiplex, particle-based assay; P: Pulmonary alveolar proteinosis; S: Sarcoidosis;
###end p 54
###begin p 55
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 199 201 199 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 209 211 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 377 379 377 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 481 483 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 652 653 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 656 658 656 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 719 720 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 723 725 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 814 815 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 820 818 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 892 897 892 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A, B</xref>
###xml 957 958 957 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 961 963 961 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1017 1019 1017 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 298 306 <span type="species:ncbi:9606">Children</span>
###xml 418 426 <span type="species:ncbi:9606">children</span>
###xml 522 530 <span type="species:ncbi:9606">children</span>
###xml 570 578 <span type="species:ncbi:9606">children</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 1074 1082 <span type="species:ncbi:9606">patients</span>
To test whether increased MCP-1 levels are associated with increased frequencies of CCR2+ T cells, BALF lymphocytes were quantified by flow cytometry. CCR2 was expressed on a higher percentage of CD4+ than CD8+ T cells. The majority of CCR2+ T cells showed an activated phenotype (75% CCR2+CD69+). Children with ILD had significantly higher percentages of CCR2+CD4+and CCR2+CD8+ T cells in BALF as compared to control children (Figure 3A). Similar to MCP-1, percentages of CCR2+CD4+ cells were significantly higher in ILD children with pulmonary fibrosis as compared to children with non-fibrotic ILD (Figure 3B). Again, the highest percentages of CCR2+CD4+ T cells were observed in the three deceased patients and CCR2+CD4+ cells related positively to the stage of ILD (Figure 4). Furthermore, percentages of CCR2+CD4+ T cells correlated negatively with FVC and TLC in ILD patients (Figures 5A, B). Pulmonary levels of MCP-1 correlated positively with CCR2+CD4+ T cells (Figure 5C). No association between MCP-1/CCR2+ cells and immunosuppressive treatment was found in ILD patients.
###end p 55
###begin p 56
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CCR2<sup>+ </sup>T cells in children with ILD</bold>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 332 334 332 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 346 348 346 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 591 593 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 17 25 <span type="species:ncbi:9606">children</span>
###xml 132 140 <span type="species:ncbi:9606">children</span>
###xml 191 199 <span type="species:ncbi:9606">children</span>
###xml 263 271 <span type="species:ncbi:9606">children</span>
###xml 542 549 <span type="species:ncbi:9606">patient</span>
###xml 626 634 <span type="species:ncbi:9606">Children</span>
###xml 771 779 <span type="species:ncbi:9606">children</span>
CCR2+ T cells in children with ILD. (A) Percentages of CCR2+CD4+ and CCR2+CD8+ T cells in in bronchoalveolar lavage fluid (BALF) of children with interstitial lung diseases (ILD) and healthy children. (B) Percentages of CCR2+CD4+ and CCR2+CD8+ T cells in BALF of children with and without pulmonary fibrosis. Percentages of CCR2+CD4+ and CCR2+CD8+ T cells were analyzed in BALF by flow cytometry. Pulmonary fibrosis was assessed by computed tomography according to [36,37]. Median values are shown by horizontal bars. Differences between the patient groups were tested with the Mann-Whitney U test; * p < 0.05; *** p < 0.001; Children with systemic corticosteroid therapy are shown as grey circles. P: Pulmonary alveolar proteinosis; S: Sarcoidosis; dagger symbolize the children who died due to respiratory failure.
###end p 56
###begin p 57
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 9 11 9 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CCR2<sup>+ </sup>CD4<sup>+ </sup>T cells and ILD disease severity</bold>
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 222 224 222 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 663 665 663 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 120 128 <span type="species:ncbi:9606">children</span>
###xml 614 621 <span type="species:ncbi:9606">patient</span>
###xml 696 704 <span type="species:ncbi:9606">Children</span>
###xml 841 849 <span type="species:ncbi:9606">children</span>
CCR2+ CD4+ T cells and ILD disease severity. Percentages of CCR2+CD4+ T cells in bronchoalveolar lavage fluid (BALF) of children with interstitial lung disease (ILD) related to ILD disease severity. Percentages of CCR2+CD4+ T cells were analyzed in BALF by flow cytometry. ILD disease severity was scored according to the ILD score of Fan(40): 1 = asymptomatic, no desaturation; 2 = symptomatic but normoxic (> 90%) under all conditions; 3 = symptomatic with desaturation during sleep or with exercise; 4 = symptomatic with desaturation at rest; Median values are shown by horizontal bars. Differences between the patient groups were tested with the Mann-Whitney U test; * p < 0.05, ** p < 0.01; Children with systemic corticosteroid therapy are shown as grey circles. P: Pulmonary alveolar proteinosis; S: Sarcoidosis; dagger symbolize the children who died due to respiratory failure.
###end p 57
###begin p 58
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CCR2<sup>+</sup>CD4<sup>+ </sup>T cells and lung function parameters in children with ILD</bold>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 303 301 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 430 432 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 50 58 <span type="species:ncbi:9606">children</span>
###xml 215 223 <span type="species:ncbi:9606">children</span>
###xml 343 351 <span type="species:ncbi:9606">children</span>
CCR2+CD4+ T cells and lung function parameters in children with ILD. Correlation of CCR2+CD4+ T cells in bronchoalveolar lavage fluid (BALF) with (A) forced vital capacity (FVC) and (B) total lung capacity (TLC) in children with interstitial lung diseases (ILD). Correlation of percentages of CCR2+CD4+ T cells with levels of MCP-1 in BALF of children with ILD (C). FVC and TLC are shown as % of predicted. Percentages of CCR2+CD4+ T cells were analyzed in BALF by flow cytometry. P: Pulmonary alveolar proteinosis; S: Sarcoidosis
###end p 58
###begin p 59
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 290 292 290 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 164 172 <span type="species:ncbi:9606">children</span>
###xml 315 323 <span type="species:ncbi:9606">children</span>
To verify if increased levels of MCP-1 and percentages of CCR2+ T cells are characteristic for pediatric ILD, we analyzed these markers in ten selected age-matched children with well-characterized allergic asthma who are described in detail in a previous study[42]. Levels of MCP-1 and CCR2+ T cells from asthmatic children were in the range of the control group and did not correlate with each other (data not shown).
###end p 59
###begin p 60
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 593 594 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 597 599 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 644 649 644 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A, B</xref>
###xml 755 756 755 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 759 761 759 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 778 783 778 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A, B</xref>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 188 195 <span type="species:ncbi:9606">patient</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 268 275 <span type="species:ncbi:9606">patient</span>
###xml 451 458 <span type="species:ncbi:9606">patient</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
###xml 694 701 <span type="species:ncbi:9606">patient</span>
To assess the value of CCR2+CD4+ T cells and MCP-1 levels in the longitudinal course, three consecutive therapeutical BALs were analyzed in three patients with PAP (P17, P18, P19) and one patient with cholesterol pneumonitis (P22). Two PAP patients (P17, P19) and the patient with cholesterol pneumonitis worsened in the clinical course continuously (increasing oxygen requirement, increasing dyspnoe) and died from respiratory failure, while one PAP patient remained clinically stable (P18). The deceased PAP patients had continuously rising levels of MCP-1 and increasing percentages of CCR2+CD4+ T cells in the three follow-up BALs (Figures 6A, B; black circles) while the clinically stable patient showed steady levels of MCP-1 and percentages of CCR2+CD4+ T cells (Figures 6A, B; white circles).
###end p 60
###begin p 61
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Longitudinal analysis of MCP-1 levels and CCR2<sup>+</sup>CD4<sup>+ </sup>T cells</bold>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 119 121 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 687 688 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 691 693 681 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 195 203 <span type="species:ncbi:9606">children</span>
###xml 251 259 <span type="species:ncbi:9606">children</span>
###xml 308 313 <span type="species:ncbi:9606">child</span>
###xml 353 358 <span type="species:ncbi:9606">child</span>
###xml 396 401 <span type="species:ncbi:9606">child</span>
###xml 486 491 <span type="species:ncbi:9606">child</span>
Longitudinal analysis of MCP-1 levels and CCR2+CD4+ T cells. Longitudinal analysis of (A) MCP-1 levels and (B) CCR2+CD4+ T cells in three consecutive bronchoalveolar lavage fluids (BALF) of four children with interstitial lung diseases, including two children with pulmonary alveolar proteinosis (P) and one child with cholesterol pneumonitis (CP). The child with cholesterol pneumonitis and one child with pulmonary alveolar proteinosis died by respiratory failure (dagger), while one child with pulmonary alveolar proteinosis stayed clinically stable. dagger symbolize the childen who died. MCP-1 levels were quantified in BALF by a multiplex, particle-based assay. Percentages of CCR2+CD4+ T cells were analyzed in BALF by flow cytometry.
###end p 61
###begin title 62
Th1- and Th2-lymphocytes and cytokines in BALF
###end title 62
###begin p 63
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 110 112 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 146 148 146 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
To test whether increased CCR2+ T cells and levels of MCP-1 were paralleled by a pulmonary Th1/Th2-shift, CCR4+ and CCR3+(Th2) and CCR5+an d CXCR3+ (Th1) cells were determined in BALF together with an array of pulmonary Th1/Th2 cytokines.
###end p 63
###begin p 64
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 316 318 316 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 327 329 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 410 415 410 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B, C</xref>
###xml 0 8 <span type="species:ncbi:9606">Children</span>
###xml 103 111 <span type="species:ncbi:9606">children</span>
###xml 386 393 <span type="species:ncbi:9606">patient</span>
Children with ILD had significantly higher percentages of CCR4+CD4+ (Th2) cells as compared to control children (Figure 7A). CCR4 was predominantly expressed on CD4+ cells. The majority of CCR4+CD4+ cells had an activated phenotype (68% CCR4+CD69+). CCR3+ (Th2) cells were not detectable in BALF. Percentages of CCR5+ and CXCR3+ T cells (both Th1) were low and did not differ among the patient groups (Figures 7B, C).
###end p 64
###begin p 65
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 33 35 33 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pulmonary CCR4<sup>+</sup>, CCR5<sup>+</sup>, and CXCR3<sup>+ </sup>T cells</bold>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 111 113 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 130 132 130 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 145 147 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 310 311 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 317 318 317 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 332 333 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 355 356 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 527 529 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 207 215 <span type="species:ncbi:9606">children</span>
###xml 478 485 <span type="species:ncbi:9606">patient</span>
Pulmonary CCR4+, CCR5+, and CXCR3+ T cells. Percentages of (A) CCR4+CD4+, CCR4+CD8+, (B) CCR5+CD4+ and CCR5+CD8+ and (C) CXCR3+CD4+ and CXCR3+CD8+ T cells in bronchoalveolar lavage fluid (BALF) are shown in children with interstitial lung diseases (ILD) and healthy controls. Percentages of CCR4+CD4+, CCR4+CD8+, CCR5+CD4+, CCR5+CD8+, CXCR3+CD4+ and CXCR3+CD8+ T cells were analyzed in BALF by flow cytometry. Median values are shown by horizontal bars. Differences between the patient groups were tested with the Mann-Whitney U test; * p < 0.05; ** p < 0.01
###end p 65
###begin p 66
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 120 127 <span type="species:ncbi:9606">patient</span>
Levels of IFN-gamma were increased in ILD patients (p < 0.05), whereas the remaining cytokines did not differ among the patient groups (data not shown).
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 222 224 222 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 955 956 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1146 1147 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1200 1201 1200 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1536 1538 1536 1538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 708 716 <span type="species:ncbi:9606">children</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
###xml 1239 1247 <span type="species:ncbi:9606">children</span>
###xml 1430 1437 <span type="species:ncbi:9606">patient</span>
###xml 1463 1471 <span type="species:ncbi:9606">children</span>
The present work demonstrates that BALF levels of MCP-1 are consistently increased in pediatric ILD. This is accompanied by increased frequencies of the corresponding CCR2 + T cells. Levels of MCP-1 and frequencies of CCR2+ T cells were higher in fibrotic than in non-fibrotic forms of ILD and correlated with restrictive lung function parameters and ILD disease severity, indicating a relevance of the MCP-1/CCR2 axis in the pathogenesis of pediatric ILD. Infiltrating T cells are a characteristic feature of pulmonary tissue from ILD patients[45] and T cells in BALF were found to correlate with T cells in pulmonary tissue[46]. In line with previous findings[47,48], T cells were increased in BALF of our children with ILD as compared to control patients, suggesting a contribution of T cells to the pathogenesis of pediatric ILD. Studies in adult patients indicated that MCP-1 plays a role in the pathogenesis of different forms of ILD, including IPF[9,12,13], PAP[11,14], sarcoidosis[12], scleroderma with lung involvement[49] and granulomatous lung diseases[50]. Serum levels of MCP-1 were significantly elevated in adult patients with ILD[9,51] and were closely related to the clinical course[9]. However, as outlined above, ILD in children differs noticeably from ILD in adulthood. Pediatric ILD is extremely rare and little data exist with respect to pathoimmunological mechanisms. Thus, it is very hard to study a large patient group and to find enough children for each ILD subtype. We found elevated levels of MCP-1 and CCR2+ T cells in various etiologies of ILD, which suggests a common pulmonary T cell response for various forms of pediatric ILD.
###end p 68
###begin p 69
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 504 506 504 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 601 603 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 724 726 724 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 900 902 900 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1087 1089 1087 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1405 1407 1405 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1625 1636 1625 1636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aspergillus</italic>
###xml 1743 1745 1743 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 147 155 <span type="species:ncbi:9606">children</span>
###xml 272 277 <span type="species:ncbi:10090">mouse</span>
###xml 408 416 <span type="species:ncbi:9606">children</span>
###xml 524 532 <span type="species:ncbi:9606">children</span>
###xml 663 671 <span type="species:ncbi:9606">children</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
###xml 1017 1025 <span type="species:ncbi:9606">patients</span>
###xml 1270 1278 <span type="species:ncbi:9606">children</span>
###xml 1551 1559 <span type="species:ncbi:9606">children</span>
###xml 1654 1659 <span type="species:ncbi:10090">mouse</span>
Thus far, frequencies of BALF CCR2+ T cells in human ILD have not been determined. The parallel increase of MCP-1 and CCR2+ T cells in BALF of ILD children further substantiates the importance of this chemokine and its receptor in the pathogenesis of ILD, as suggested by mouse models. In these models, the relevance of the MCP-1/CCR2 interaction was mainly addressed with respect to pulmonary fibrosis. Our children with pulmonary fibrosis had increased levels of MCP-1 and increased percentages of CCR2+ cells compared to children with non-fibrotic ILD. However, MCP-1 levels and percentages of CCR2+ T cells were elevated both in fibrotic and non-fibrotic ILD children as compared to controls. In addition, MCP-1 and CCR2+ T cells were also elevated in pediatric PAP that usually does not progress to pulmonary fibrosis. In fact, one of the three patients with the highest levels of MCP-1 and CCR2+ T cells had PAP without any indication of fibrosis. Similar observations were made recently for MCP-1 in adult PAP patients[11]. A possible biological relevance of MCP-1 levels and CCR2+ T cells in pediatric ILD is further suggested by their correlation with restrictive lung function parameters and the ILD disease severity score and by the finding that the deceased children with the most severe course of disease exhibited the highest BALF levels of these markers. The possibility that MCP-1 and CCR2+ T cells are a general phenomenon of pediatric lung diseases seems very unlikely, since these markers were present only at low levels in BALF of children with severe allergic asthma. This is in line with findings in an Aspergillus-induced allergic mouse model, where a Th2-mediated lung pathology occured in the absence of MCP-1 or CCR2[52].
###end p 69
###begin p 70
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 340 342 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 427 429 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 487 489 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 84 92 <span type="species:ncbi:9606">children</span>
###xml 149 157 <span type="species:ncbi:9606">children</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 213 220 <span type="species:ncbi:9606">patient</span>
###xml 270 278 <span type="species:ncbi:9606">children</span>
###xml 368 375 <span type="species:ncbi:9606">patient</span>
To assess the value of CCR2+ T cells and MCP-1 levels in the longitudinal course of children with ILD, three consecutive BALs were performed in four children with ILD including three ILD patients who died and one patient who stayed clinically stable. The three deceased children had high and continuously rising levels of MCP-1 and CCR2+CD4+ T cells, while the stable patient had low levels of MCP-1 and percentages of CCR2+CD4+ T cells. Thus, levels of MCP-1 and percentages of CCR2+CD4+ T cells might reflect the disease progression in pediatric ILD.
###end p 70
###begin p 71
###xml 99 101 99 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">children</span>
Interestingly, immunosuppressive treatment was not associated with altered levels of MCP-1 and CCR2+ T cells in BALF (data not shown). This is in contrast to a study of Suga et al.[9] in adult ILD patients where serum levels of MCP-1 were closely related to the effectiveness of corticosteroid therapy. Given the assumption that MCP-1 and CCR2 are important players in the pathophysiology of ILD in children, the lack of association with corticosteroid therapy might explain, at least in part, why corticosteroids are sometimes unable to control the progression of pediatric ILD.
###end p 71
###begin p 72
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 484 486 484 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 577 578 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 581 583 581 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 757 759 757 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 942 944 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 995 997 995 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1207 1209 1207 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1316 1318 1316 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 457 465 <span type="species:ncbi:9606">children</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
###xml 789 794 <span type="species:ncbi:10090">mouse</span>
###xml 1034 1042 <span type="species:ncbi:9606">children</span>
###xml 1064 1072 <span type="species:ncbi:9606">children</span>
###xml 1252 1260 <span type="species:ncbi:9606">patients</span>
###xml 1359 1367 <span type="species:ncbi:9606">children</span>
Several studies indicated that MCP-1 and CCR2 are involved in Th1[53,54] and Th2 immunity [55-58]. Furthermore, it has been suggested that ILD and pulmonary fibrosis are associated with a Th2 immune response[20-22,59-61]. Experiments in mice showed that a lack of MCP-1[62] leads to decreased Th1 responses while MCP-1 over-expression[58] results in increased levels of Th2 cytokines. Th1/Th2 cytokine levels in BALF were low or undetectable in BALF of our children. However, CCR4+CD4+ T cells were moderately but significantly elevated in ILD patients. On the other hand, CCR4+CD4+ T cells are clearly less frequent in ILD compared to allergic asthma[42]. Thus, a strong Th2 response seems unlikely in our ILD patients. Beneath T-cells, MCP-1 attracts CCR2+ monocytes/macrophages[63]. In mouse models, MCP-1 was found to attract monocytes to the inflamed lung, which was accompanied by a concomitant downregulation of pulmonary MCP-1 levels[64]. We found no difference in the percentage of CCR2+ alveolar macrophages in BALF between children with ILD and control children or between fibrotic and non-fibrotic forms of ILD (data not shown). Instead, we found a strong correlation between percentages of CCR2+ T cells and levels of MCP-1 in BALF of ILD patients. Therefore, we assume that pulmonary MCP-1 acts on CCR2+ T cells, which accumulate in the BALF of children with ILD.
###end p 72
###begin title 73
Conclusion
###end title 73
###begin p 74
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 90 98 <span type="species:ncbi:9606">children</span>
###xml 368 376 <span type="species:ncbi:9606">children</span>
In conclusion, CCR2+ T cells and levels of MCP-1 are characteristic components in BALF of children with ILD. A pathophysiological role in pediatric ILD seems likely as their levels relate to restrictive lung function and ILD disease severity. Therefore, pharmacological targeting of the MCP-1/CCR2 axis might represent an additional option for the treatment of ILD in children.
###end p 74
###begin title 75
Abbreviations
###end title 75
###begin p 76
BAL(F): Bronchoalveolar lavage (fluid)
###end p 76
###begin p 77
CC: CC chemokine receptor
###end p 77
###begin p 78
CXC: CXC chemokine receptor
###end p 78
###begin p 79
FVC: Forced vital capacity
###end p 79
###begin p 80
IFN-gamma: Interferon-gamma
###end p 80
###begin p 81
IL-: Interleukin
###end p 81
###begin p 82
IPF: Idiopathic pulmonary fibrosis
###end p 82
###begin p 83
IPH: Idiopathic pulmonary hemosiderosis
###end p 83
###begin p 84
LIP: Lymphocytic interstitial pneumonia
###end p 84
###begin p 85
MCP-1: Monocyte chemotactic protein 1 (CCL2)
###end p 85
###begin p 86
PAP: Pulmonary alveolar proteinosis
###end p 86
###begin p 87
TGF-beta: Transforming growth factor beta
###end p 87
###begin p 88
Th1/Th2: T helper cell 1/2
###end p 88
###begin p 89
TLC: Total lung capacity
###end p 89
###begin p 90
TNF-alpha: Tumor necrosis factor-alpha
###end p 90
###begin title 91
Competing interests
###end title 91
###begin p 92
The author(s) declare that they have no competing interests.
###end p 92
###begin title 93
Authors' contributions
###end title 93
###begin p 94
###xml 217 224 <span type="species:ncbi:9606">patient</span>
DH carried out the experimental analyses and wrote the manuscript. MG characterized the study population, performed bronchoalveolar lavage and participated in the study design. TN performed bronchoalveolar lavage and patient characterization. GZ and CP participated in the experimental analyses. DR and DJS participated in the study design and reviewed the manuscript. SKE designed the study, supervised the experimental analyses and wrote the manuscript. All authors read and approved the final manuscript.
###end p 94
###begin title 95
Acknowledgements
###end title 95
###begin p 96
This work was supported by grants from the Else-Kroner-Fresenius Stiftung, the Friedrich-Baur-Stiftung, by a grant of the University and Science Program of the Ludwig-Maximilians-University (HWP) and by the Clinical Cooperation Groups "Pediatric Immune Regulation" and "Immune Monitoring". We thank Cory M. Hogaboam, Department of Pathology, University of Michigan Medical School, Ann Arbor, for helpful discussions and critical revision of the mansucript.
###end p 96
###begin article-title 97
###xml 67 75 <span type="species:ncbi:9606">children</span>
Task force on chronic interstitial lung disease in immunocompetent children
###end article-title 97
###begin article-title 98
Diagnosis of interstitial lung disease
###end article-title 98
###begin article-title 99
###xml 29 37 <span type="species:ncbi:9606">children</span>
Interstitial lung disease in children - genetic background and associated phenotypes
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 64 69 <span type="species:ncbi:9606">Human</span>
Human Monocyte Chemoattractant Protein-1 (MCP-1) - Secretion by Human-Fibroblasts
###end article-title 100
###begin article-title 101
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 167 172 <span type="species:ncbi:10090">Mouse</span>
Human Monocyte Chemoattractant Protein-1 (MCP-1) - Full-Length Cdna Cloning, Expression in Mitogen-Stimulated Blood Mononuclear Leukocytes, and Sequence Similarity to Mouse Competence Gene Je
###end article-title 101
###begin article-title 102
Induction of MCP-1 expression in airway epithelial cells: Role of CCR2 receptor in airway epithelial injury
###end article-title 102
###begin article-title 103
Costimulation of fibroblast collagen and transforming growth factor beta(1) gene expression by monocyte chemoattractant protein-1 via specific receptors
###end article-title 103
###begin article-title 104
###xml 87 93 <span type="species:ncbi:10090">murine</span>
Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1-and Th2-type pulmonary granuloma models
###end article-title 104
###begin article-title 105
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases
###end article-title 105
###begin article-title 106
Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis
###end article-title 106
###begin article-title 107
Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppression
###end article-title 107
###begin article-title 108
###xml 63 71 <span type="species:ncbi:9606">Patients</span>
Elevated Il-8 and Mcp-1 in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis
###end article-title 108
###begin article-title 109
Monocyte Chemoattractant Protein-1 in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung-Diseases
###end article-title 109
###begin article-title 110
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis
###end article-title 110
###begin article-title 111
Monocyte Chemoattractant Protein-1 Acts As A T-Lymphocyte Chemoattractant
###end article-title 111
###begin article-title 112
International union of pharmacology. XXII. Nomenclature for chemokine receptors
###end article-title 112
###begin article-title 113
###xml 94 98 <span type="species:ncbi:10090">mice</span>
The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice
###end article-title 113
###begin article-title 114
Protection from pulmonary fibrosis in the absence of CCR2 signaling
###end article-title 114
###begin article-title 115
Fibrotic disease and the Th1/Th2 paradigm
###end article-title 115
###begin article-title 116
Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis
###end article-title 116
###begin article-title 117
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia
###end article-title 117
###begin article-title 118
Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia
###end article-title 118
###begin article-title 119
Lymphokine Regulation of Inflammatory Processes - Interleukin-4 Stimulates Fibroblast Proliferation
###end article-title 119
###begin article-title 120
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Fibroblasts Synthesize Elevated Levels of Extracellular-Matrix Proteins in Response to Interleukin-4
###end article-title 120
###begin article-title 121
Gamma-Interferon Is the Lymphokine and Beta-Interferon the Monokine Responsible for Inhibition of Fibroblast Collagen Production and Late But Not Early Fibroblast Proliferation
###end article-title 121
###begin article-title 122
Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures
###end article-title 122
###begin article-title 123
###xml 66 71 <span type="species:ncbi:9606">human</span>
Negative modulation of (alpha 1(I) procollagen gene expression in human skin fibroblasts: Transcriptional inhibition by interferon-gamma
###end article-title 123
###begin article-title 124
Interferon-gamma inhibits experimental renal fibrosis
###end article-title 124
###begin article-title 125
###xml 97 101 <span type="species:ncbi:10116">rats</span>
Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: Macrophages as a prominent source of interleukin-4
###end article-title 125
###begin article-title 126
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 162 170 <span type="species:ncbi:9606">Patients</span>
In vitro Production of B-Cell Growth-Factor and B-Cell Differentiation Factor by Peripheral-Blood Mononuclear-Cells and Bronchoalveolar Lavage Lymphocytes-T from Patients with Idiopathic Pulmonary Fibrosis
###end article-title 126
###begin article-title 127
###xml 93 101 <span type="species:ncbi:9606">Patients</span>
###xml 141 144 <span type="species:ncbi:31658">CFA</span>
A Type-2 (Th2-Like) Pattern of Immune-Response Predominates in the Pulmonary Interstitium of Patients with Cryptogenic Fibrosing Alveolitis (CFA)
###end article-title 127
###begin article-title 128
###xml 38 46 <span type="species:ncbi:9606">Children</span>
Pediatric interstitial lung disease - Children are not small adults
###end article-title 128
###begin article-title 129
Evaluation of a diagnostic approach to pediatric interstitial lung disease
###end article-title 129
###begin article-title 130
Standardization of Spirometry - 1994 Update
###end article-title 130
###begin article-title 131
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias
###end article-title 131
###begin article-title 132
Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring
###end article-title 132
###begin article-title 133
Diagnostic accuracy of thin-section CT and chest radiography of pediatric interstitial lung disease
###end article-title 133
###begin article-title 134
###xml 62 69 <span type="species:ncbi:9606">infants</span>
###xml 75 83 <span type="species:ncbi:9606">children</span>
Classification of pulmonary alveolar proteinosis in newborns, infants, and children
###end article-title 134
###begin article-title 135
Idiopathic pulmonary fibrosis: Diagnosis and treatment - International consensus statement
###end article-title 135
###begin article-title 136
###xml 65 73 <span type="species:ncbi:9606">children</span>
Open lung biopsy in the investigation of diffuse lung disease in children
###end article-title 136
###begin article-title 137
###xml 37 45 <span type="species:ncbi:9606">Children</span>
Chronic Interstitial Lung-Disease in Children
###end article-title 137
###begin article-title 138
###xml 55 63 <span type="species:ncbi:9606">children</span>
Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough
###end article-title 138
###begin article-title 139
###xml 23 31 <span type="species:ncbi:9606">children</span>
Airway inflammation in children with tracheostomy
###end article-title 139
###begin article-title 140
Idiopathic pulmonary fibrosis - Clinical relevance of pathologic classification
###end article-title 140
###begin article-title 141
Lung lymphocytes: Origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders
###end article-title 141
###begin article-title 142
###xml 26 34 <span type="species:ncbi:9606">children</span>
Bronchoalveolar lavage in children with chronic diffuse parenchymal lung disease
###end article-title 142
###begin article-title 143
###xml 7 15 <span type="species:ncbi:9606">children</span>
BAL in children - A controlled study of differential cytology and cytokine expression profiles by alveolar cells in pediatric sarcoidosis
###end article-title 143
###begin article-title 144
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Gene expression in bronchoalveolar lavage cells from scleroderma patients
###end article-title 144
###begin article-title 145
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases
###end article-title 145
###begin article-title 146
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases
###end article-title 146
###begin article-title 147
Aspergillus antigen induces robust Th2 cytokine production, inflammation, airway hyperreactivity and fibrosis in the absence of MCP-1 or CCR2
###end article-title 147
###begin article-title 148
Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity
###end article-title 148
###begin article-title 149
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
###end article-title 149
###begin article-title 150
Effect of C-C chemokine receptor 2 (CCR2) knockout on Schistosomal egg antigen-elicited granuloma formation and the regional lymphoid response
###end article-title 150
###begin article-title 151
Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1
###end article-title 151
###begin article-title 152
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2)
###end article-title 152
###begin article-title 153
Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of Th1 and Th2 type responses in vivo
###end article-title 153
###begin article-title 154
The role of the Th2CC chemokine ligand CCL17 in pulmonary fibrosis
###end article-title 154
###begin article-title 155
Cytokine Networking in Lung Inflammation
###end article-title 155
###begin article-title 156
Plunging into the chaos of the cytokine/chemokine cocktail in pulmonary fibrosis - How many and how important are they?
###end article-title 156
###begin article-title 157
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice
###end article-title 157
###begin article-title 158
###xml 94 98 <span type="species:ncbi:10090">mice</span>
The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice
###end article-title 158
###begin article-title 159
CCR2-positive monocytes recruited to inflamed lungs downregulate local CCL2 chemokine levels
###end article-title 159

